VMD-928

Customer Review

Based on 1 Customer Validation

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma.

For research use only. We do not sell to patients.

  • Purity: 98.12%
  • CAS No.: 1802770-18-8
  • Formula: C31H32N4O4
  • Molecular Weight:524.61
  • Storage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs

All Trk Receptor Isoforms

More
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00